Using brain stimulation to reduce cravings and improve control in people with substance use disorders
Official title: Modification of Inhibitory Control and Craving Through Transcranial Direct Current Stimulation (tDCS) as an Add-On Treatment for Substance Use Disorder
Run by Central Institute of Mental Health, Mannheim · NCT06959342 · Data updated 2026-11-12
This study is testing if a type of brain stimulation can help people with alcohol use disorder feel less cravings and have better control during their detox treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 162 (estimated) |
| Sponsor | Central Institute of Mental Health, Mannheim Academic / other |
| Locations | 2 sites (Mannheim and 1 other locations) |
| Status | Recruiting |
| Started | September 23, 2024 |
| Main results expected | March 31, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | June 4, 2025 |
| Trial ID | NCT06959342 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 18 to 65 with a primary diagnosis of alcohol use disorder who are undergoing detoxification treatment.
✕Probably not a fit
Patients with severe psychiatric comorbidities or those currently experiencing severe withdrawal symptoms may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project investigates the use of transcranial direct current stimulation (tDCS) to enhance inhibitory control and reduce cravings in individuals with substance use disorders, particularly focusing on alcohol use disorder. Participants aged 18 to 65 undergoing detoxification treatment will receive different tDCS protocols, including active and sham conditions, to determine the most effective settings for improving treatment outcomes. The study will assess cognitive performance through neuropsychological testing and EEG recordings to identify optimal stimulation parameters. The goal is to enhance the effectiveness of standard detoxification treatments by integrating tDCS as an adjunctive therapy.
Why it matters
Potential benefit: If successful, this approach could lead to improved treatment outcomes, including longer periods of abstinence and reduced substance use after relapse.
How similar studies have gone: While there are conflicting findings regarding tDCS effectiveness in substance use disorders, this study aims to clarify its potential benefits, making it a novel approach in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * main diagnosis: alcohol use disorder according to DSM-5 * patients of any gender aged 18 to 65 * normal vision or correctable visual impairment. * sufficient ability to communicate verbally and in writing * ability to give fully informed consent after reviewing thorough written information Exclusion Criteria: * withdrawal of consent * severe internal, neurological, or psychiatric comorbidities (e.g., lifetime schizophrenia, bipolar disorder, or other severe mental disorders according to ICD-10 and DSM-5, such as severe depression or PTSD within the last 12 months). * Exclusion criteria for an EEG/tDCS examination (e.g. metal implants in the head, epilepsy, etc.) * severe withdrawal symptoms (CIWA-R \> 7) * alcohol intoxication (breath alcohol concentration \> 0 ‰) * Pharmacotherapy with psychoactive substances within the last 14 days (exceptions: clomethiazole or benzodiazepines used in withdrawal treatment, provided they were discontinued at least 3 days prior; antidepressants or anxiolytics taken at stable doses). * drug or alcohol use within the last 7 days * for women: pregnancy * suicidal tendencies or danger to others
Where it's running
-
Central Institute of Mental Health
Mannheim, Germany Recruiting -
Psychiatrisches Zentrum Nordbaden (Psychiatric Center Nordbaden)
Wiesloch, Germany Not yet recruiting
Study contacts
- Study coordinator: Sabine Vollstädt-Klein, PhD
- Email: Sabine.Vollstaedt-Klein@zi-mannheim.de
- Phone: +4962117033912
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of comorbidity on people with severe mental illness
This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.
-
Transcutaneous auricular neurostimulation (tAN) for reducing alcohol withdrawal in people with alcohol use disorder
This trial will try a five-day ear‑stimulation device (tAN) versus a sham device to reduce alcohol withdrawal symptoms in adults with moderate-to-severe alcohol use disorder.
-
Impact of MOUD Policy Changes During the Pandemic on Opioid and Alcohol Use Disorders
This study tests how federal and state policy changes during the COVID-19 pandemic affected access to and use of medications for opioid use disorder among Veterans with opioid or alcohol use disorders.
-
New blood test to help identify and track depression and early schizophrenia
This project will try a new blood test to see if it can identify and track depression or early schizophrenia in adults receiving psychiatric care.
-
Engagement of community health workers to support recovery from substance use disorders
This study is testing whether support from community health workers can help people with substance use disorders engage better in treatment and improve their recovery experience after visiting the emergency department.
-
One-year Parent-Child Assistance Program for parents with recent substance use
This project will test whether a one-year Parent-Child Assistance Program helps parents who used substances during pregnancy stay with or reunify with their children and support their recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.